RxDoctor Payments DataLook up a doctor →

Jennifer Murdoch

Nurse Practitioner · Portland, ORNPI 1891843397

Payments from drug & device makers

$14,735in general payments, 2019–2025

Across 638 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$2K
  • Amgen$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Xeris Pharmaceuticals, Inc.$825
  • Abbott$745
  • plus $6K from 41 others

What the payments were for

  • Speaking & faculty fees$1,3509%
  • Travel & lodging$630%
  • Food & beverage$13,23690%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,735 in reported general payments places this provider in the 95th percentile of 997 nurse practitioner providers in Oregon.

See all nurse practitioner providers in Oregon

Medicare billing

Part B allowed, 2024
$98,456
Medicare patients
215
Services billed
3,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide269$459,738
JardianceEmpagliflozin207$313,557
MounjaroTirzepatide172$262,432
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog62$153,847
TrulicityDulaglutide44$58,813
Humalog Kwikpen U-100Insulin Lispro134$58,537
Humulin R U-500 KwikpenInsulin Regular, Human12$55,513
Humalog Kwikpen U-200Insulin Lispro14$54,151
Tresiba Flextouch U-100Insulin Degludec46$52,440
Tresiba Flextouch U-200Insulin Degludec25$50,639
Humulin R U-500Insulin Regular, Human15$38,551
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog50$36,181
Lantus SolostarInsulin Glargine,hum.Rec.Anlog169$34,302
Repatha SureclickEvolocumab29$32,546
RybelsusSemaglutide11$30,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,654$495,666291 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Humalog Mix 75-25, Insulin Lispro$1,175$343,994288 claims
Boehringer IngelheimJardiance$677$313,557207 claims
AstraZenecaFarxiga$580$21,65633 claims
Sanofi-aventis U.S. LLCLantus$211$9,95332 claims
AbbVieSynthroid$146$3,09632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 997 nurse practitioner providers in Oregon.

Other nurse practitioner in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →